Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Statistics in Medicine|November 6, 2007
Adjusting for verification bias in diagnostic test evaluation: a Bayesian approachManuela Buzoianu, Joseph B KadaneBiometrics|November 22, 2008
Optimal Bayesian design for patient selection in a clinical studyManuela Buzoianu, Joseph B KadaneJournal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Sex-specific Long-term Outcomes of Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial FibrillationHongying Jiang, Qi Zheng, Yun-Ju Cheng, et al.Investigational New Drugs|February 29, 2012
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsChristina M Annunziata, Elise C Kohn, Patricia LoRusso, et al.Therapeutic Innovation & Regulatory Science|January 11, 2023
Some Thoughts on the Use of Predictive Probability in Clinical TrialsHeng Li, Manuela Buzoianu, Adrijo Chakraborty, et al.Cancer|January 29, 2010
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanomaPeter Hersey, Jeffrey Sosman, Steven O'Day, et al.Plos One|August 31, 2013
Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical studyHaifeng Bao, Patricia A Burke, Jiaqi Huang, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 8, 2005
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunctionAlin L Girnita, Rene Duquesnoy, Samuel A Yousem, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanomaStergios J Moschos, Cindy A Sander, Wenjun Wang, et al.Pageof 1